{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:39:50Z","timestamp":1793353190149,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rmed.2025.108464","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:53:52Z","timestamp":1761724432000},"page":"108464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Discontinuation of supportive therapies in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor \u2013 A patient-reported outcomes\u2019 study"],"prefix":"10.1016","volume":"249","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3384-5101","authenticated-orcid":false,"given":"S.","family":"Ahting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-1249","authenticated-orcid":false,"given":"M.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wollschl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Henn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3724-954X","authenticated-orcid":false,"given":"C.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-L.","family":"Strehlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"vom Hove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hentschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Prenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rmed.2025.108464_bib1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2025.108464_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"8","key":"10.1016\/j.rmed.2025.108464_bib3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Lopes-Pacheco","year":"2021","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.rmed.2025.108464_bib4","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"10212","key":"10.1016\/j.rmed.2025.108464_bib5","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.rmed.2025.108464_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108464_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-tezacaftor-ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.rmed.2025.108464_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/children10030554","article-title":"Efficacy and safety of elexacaftor-tezacaftor-ivacaftor in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Kapouni","year":"2023","journal-title":"Children"},{"issue":"14","key":"10.1016\/j.rmed.2025.108464_bib9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","article-title":"What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2025.108464_bib10","first-page":"122","volume":"vol. 38","author":"Basch","year":"2018"},{"issue":"2","key":"10.1016\/j.rmed.2025.108464_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2025.108464_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rmed.2025.108464_bib13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis: the importance of reducing treatment burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.rmed.2025.108464_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2025.108464_bib15","article-title":"Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: a retrospective review","author":"Guenther","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2025.108464_bib18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108464_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.108464_bib20","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2022.05.005","article-title":"Research letter: the impact of elexacaftor\/tezacaftor\/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis","volume":"21","author":"Song","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2025.108464_bib21","article-title":"Medication utilization and lung function changes after initiation of treatment with elexacaftor\/tezacaftor\/ivacaftor","author":"Vuyst","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2025.108464_bib22","series-title":"Sosci Survey","author":"Leiner","year":"2019"},{"key":"10.1016\/j.rmed.2025.108464_bib23","volume":"vol. 26","author":"N\u00e4hrlich","year":"2024"},{"key":"10.1016\/j.rmed.2025.108464_bib24","series-title":"R: a Language and Environment for Statistical Computing","year":"2025"},{"key":"10.1016\/j.rmed.2025.108464_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3310\/nihropenres.13260.1","article-title":"Exploring the nature of perceived treatment burden: a study to compare treatment burden measures in adults with cystic fibrosis version 1; peer review: 2 approved","volume":"2","author":"Altabee","year":"2022","journal-title":"NIHR Open Res"},{"key":"10.1016\/j.rmed.2025.108464_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241235054","article-title":"Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor combination: a 1-year observational study","volume":"18","author":"Blardone","year":"2024","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"3","key":"10.1016\/j.rmed.2025.108464_bib27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2019.10.025","article-title":"Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials","volume":"19","author":"Davies","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.rmed.2025.108464_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.10.009","article-title":"Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen et al","volume":"19","author":"Olesen","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"7","key":"10.1016\/j.rmed.2025.108464_bib29","article-title":"The effects of elexacaftor, tezacaftor, and ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review","volume":"15","author":"Salazar-Barragan","year":"2023","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.rmed.2025.108464_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1015","article-title":"Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients","volume":"10","author":"Kos","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.rmed.2025.108464_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fspor.2024.1284878","article-title":"Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor\/tezacaftor\/ivacaftor","volume":"6","author":"Gruber","year":"2024","journal-title":"Front Sports Act Living"},{"key":"10.1016\/j.rmed.2025.108464_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2025.108464_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27100","article-title":"Mental health, sleep, and respiratory health after initiating elexacaftor\/tezacaftor\/ivacaftor treatment in children with cystic fibrosis","author":"Pham","year":"2024","journal-title":"Pediatr. Pulmonol."},{"issue":"10448","key":"10.1016\/j.rmed.2025.108464_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(24)01134-6","article-title":"Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis","volume":"404","author":"Sermet-Gaudelus","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rmed.2025.108464_bib35","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2025.108464_bib36","article-title":"Why do patients often lie to their doctors?","volume":"191","author":"Vogel","year":"2019","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"issue":"12","key":"10.1016\/j.rmed.2025.108464_bib37","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor","volume":"55","author":"Munce","year":"2020","journal-title":"Pediatr. Pulmonol."},{"issue":"4","key":"10.1016\/j.rmed.2025.108464_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved nutritional outcomes and gastrointestinal symptoms in adult cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2025.108464_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"11","key":"10.1016\/j.rmed.2025.108464_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102899","article-title":"Advances in cystic fibrosis-related diabetes: current status and future directions","volume":"17","author":"Lurquin","year":"2023","journal-title":"Diabetes Metabol. Syndr."},{"key":"10.1016\/j.rmed.2025.108464_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int. J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2025.108464_bib42","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108464_bib43","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.rmed.2025.108464_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12890-015-0038-7","article-title":"Adherence to treatment in children and adolescents with cystic fibrosis: a cross-sectional, multi-method study investigating the influence of beliefs about treatment and parental depressive symptoms","volume":"15","author":"Goodfellow","year":"2015","journal-title":"BMC Pulm. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108464_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ppul.23017","article-title":"Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives","volume":"50","author":"Sawicki","year":"2015","journal-title":"Pediatr. Pulmonol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108464_bib46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcf.2008.01.003","article-title":"Treatment compliance in children and adults with cystic fibrosis","volume":"7","author":"Arias","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2025.108464_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/srep10241","article-title":"Lung microbiota across age and disease stage in cystic fibrosis","volume":"5","author":"Coburn","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.rmed.2025.108464_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-Week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108464_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/17425255.2021.1836157","article-title":"The pharmacokinetics of antibiotics in cystic fibrosis","volume":"17","author":"Akkerman-Nijland","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.rmed.2025.108464_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107455","article-title":"The impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: an expert-based Delphi consensus","volume":"220","author":"Gramegna","year":"2023","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108464_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2025.108464_bib52","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00587-2024","article-title":"Variability in disease severity among cystic fibrosis patients carrying residual-function variants: data from the european cystic fibrosis society patient registry","volume":"11","author":"Mei-Zahav","year":"2025","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.rmed.2025.108464_bib53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J. Cyst. Fibros."},{"issue":"9","key":"10.1016\/j.rmed.2025.108464_bib54","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older - the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.108464_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2022.110421","article-title":"Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: early report","volume":"154","author":"Bec","year":"2022","journal-title":"Eur. J. Radiol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108464_bib56","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.rmed.2025.108464_bib57","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00519-24","article-title":"Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis","volume":"15","author":"Armbruster","year":"2024","journal-title":"mBio"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112500527X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112500527X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:02:43Z","timestamp":1763690563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461112500527X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":55,"alternative-id":["S095461112500527X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108464","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of supportive therapies in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor \u2013 A patient-reported outcomes\u2019 study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108464"}}